Our Stocks and Sips evening with Xenitra (ASX:XEN) featured a live Q&A with Dr Anthony Noble, Non-Executive Chairman, who shared insights into Xenitra's integrated digital commerce platform connecting global brands with Chinese consumers. The discussion explored XEN's three growth pillars - nutraceuticals, OTC pharmaceuticals, and real-world-asset tokenisation - alongside the company's brand partnership strategy, approach to regulatory risk, and outlook for long-term growth, followed by drinks, gourmet food, and networking at the Sharewise office.

At our latest Stocks and Sips event, we welcomed Dr Anthony Noble, Non-Executive Chairman of Xenitra Limited (ASX:XEN), for an in-depth discussion hosted by Sharewise CEO Alex Perry.
Xenitra is one of the few ASX-listed vehicles offering direct exposure to China's fast-growing consumer and healthcare markets. Through its channel-optimised sales platform - spanning B2B trading, retail distribution, and all major Chinese e-commerce platforms - XEN has generated over $70m in sales since 2024 and secured a $30m offtake agreement for global brands. The recent acquisition of Fukang OTC Pharmacy and the launch of the OPAL token and Xen Shop position the company at the intersection of cross-border FMCG, consumer healthcare, and Web3-enabled retail.
Anthony shared insights on:
The evening brought together Sharewise clients for thoughtful discussion, live Q&A, and networking over drinks and gourmet food at the Sharewise office in Milsons Point.
Join Sharewise on Thursday 7 May 2026 for an exclusive Stocks and Sips evening with Dr Anthony Noble, Non-Executive Chairman of Xenitra Limited (ASX:XEN), for a live Q&A exploring how XEN is building an integrated digital commerce ecosystem for Asian markets.
XEN is one of the few ASX-listed vehicles offering direct exposure to China's fast-growing consumer and healthcare markets. Through its channel-optimised sales platform - spanning B2B trading, retail distribution, and all major Chinese e-commerce platforms - XEN has generated over $70m in sales since 2024, with Q3 revenue of $8.3m, up more than 300% QoQ, and a $30m offtake agreement for global brands validating its execution capability. The recent acquisition of Fukang OTC Pharmacy, combined with its Hong Kong pharmaceutical licence, positions XEN to capture what management believes is a structural inflection point in China's OTC market - comparable to the infant formula boom a decade ago. Meanwhile, the launch of the OPAL token and Xen Shop places XEN at the forefront of Web3-enabled retail, with blockchain tied directly to real-world consumer goods.
After the discussion, guests are invited to stay for drinks, gourmet food, and networking in a relaxed setting at the Sharewise office in Milsons Point, with complimentary merch to take home.
Limited spaces available - reserve yours to secure your seat at this exclusive event.

Xenitra specialises in fast-moving consumer goods (FMCG), nutraceuticals, over-the-counter (OTC) medicine and personal care products that are sold through a channel optimised sales ecosystem including blockchain tokenised distribution channels spanning Business-to-Business (B2B) trading, retail distribution and all major ecommerce platforms in China. Xenitra works with leading international brands as a market entry and sales acceleration partner for Asian markets. Through our proprietary platform, we have a proven track record of delivering exceptional market integration, providing marketing insights and delivering sales velocity for brands in China.
.jpeg)
Anthony was appointed Non-Executive Chairman in March 2025. He has more than 20 years’ experience working across life sciences, consumer health, and international trade, with a focus on building partnerships and creating sustainable growth. Anthony holds a PhD in Stem Cell Biology and an Executive MBA from the Australian Graduate School of Management, including a year at the Wharton School (UPenn). His career has spanned from biotechnology research and clinical development to operational and commercial leadership roles in both listed and private companies. He currently serves as Executive Director at Servatus Biopharmaceuticals and Biomiq Skincare. He previously was CEO of The Calmer Co. Ltd and Australian Biotherapeutics. Anthony spent a decade in various roles within the SFI Health Group where he was Global Head of Innovation and spearheaded market expansion initiatives via both organic growth and multiple M&A transactions in Europe, Australia, North America and in Asia, with a strong focus on the North Asia markets, including serving as General Manager of both SFI-Shineway in China and of SFI-Korea. His focus at Xenitra has been on strengthening the company’s compliance and governance practices, tightening and defining the strategic direction, supporting senior management in China, and ensuring the business is well-positioned to take advantage of growing opportunities in cross-border trade.










Attendance is free and spots are limited. Register to receive your QR code for check-in on the night.
Yes - free (limited spots available). Registration is essential.
Sharewise, Level 9, 68 Alfred St S, Milsons Point.
Drinks: Open bar. Food: Gourmet food served during networking.
Business casual.
Yes - this is an 18+ event.
The team behind Stocks and Sips works with clients every day on research, advisory and execution across ASX, US and global markets.